Your browser doesn't support javascript.
loading
Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study.
Adams, S; Loi, S; Toppmeyer, D; Cescon, D W; De Laurentiis, M; Nanda, R; Winer, E P; Mukai, H; Tamura, K; Armstrong, A; Liu, M C; Iwata, H; Ryvo, L; Wimberger, P; Rugo, H S; Tan, A R; Jia, L; Ding, Y; Karantza, V; Schmid, P.
Afiliación
  • Adams S; Department of Medicine, Perlmutter Cancer Center, New York University School of Medicine, New York, USA. Electronic address: sylvia.adams@nyumc.org.
  • Loi S; Division of Research and Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Toppmeyer D; Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, USA.
  • Cescon DW; Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada.
  • De Laurentiis M; Dipartimento di Senologia, Istituto Nazionale Tumori - "Fondazione Pascale," Naples, Italy.
  • Nanda R; Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago.
  • Winer EP; Medical Oncology, Dana-Farber Cancer Institute, Boston, USA.
  • Mukai H; Department of Breast and Medical Oncology, National Cancer Center Hospital East, Kashiwa.
  • Tamura K; Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Armstrong A; Breast Disease Research Group, The Christie NHS Foundation Trust, Manchester, UK.
  • Liu MC; Department of Oncology, Mayo Clinic, Rochester, USA.
  • Iwata H; Aichi Cancer Center Hospital, Nagoya, Japan.
  • Ryvo L; Division of Oncology, Sourasky Medical Center (Ichilov), Tel Aviv, Israel.
  • Wimberger P; Department of Gynecology and Obstetric, University Carl Gustav Carus, TU Dresden, Dresden, Germany.
  • Rugo HS; Department of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco.
  • Tan AR; Levine Cancer Institute, Atrium Health, Charlotte.
  • Jia L; Merck & Co., Inc., Kenilworth, USA.
  • Ding Y; Merck & Co., Inc., Kenilworth, USA.
  • Karantza V; Merck & Co., Inc., Kenilworth, USA.
  • Schmid P; Centre for Experimental Cancer Medicin, Barts Cancer Institute, Queen Mary University London, London, UK.
Ann Oncol ; 30(3): 405-411, 2019 03 01.
Article en En | MEDLINE | ID: mdl-30475947
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Anticuerpos Monoclonales Humanizados / Antígeno B7-H1 / Neoplasias de la Mama Triple Negativas Tipo de estudio: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2019 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Anticuerpos Monoclonales Humanizados / Antígeno B7-H1 / Neoplasias de la Mama Triple Negativas Tipo de estudio: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2019 Tipo del documento: Article Pais de publicación: Reino Unido